Fig. 7
mTOR inhibition partially rescues bone phenotype of Egfr−/− mice. a Timeline showing experiment outline for in utero Rapamycin treatment. Pregnant mice were subcutaneously injected with 5 mg Rapamycin per kg bodyweight or Injection-vehicle twice a day on E15.5 and E16.5 b H&E staining of trabecular bone sections showing distal femurs of Egfrwt and Egfr−/− embryos on E18.5 after Rapamycin/vehicle treatment; scale: 200 µm. c Quantification of bone volume relative to total volume (BV/TV) after rapamycin/vehicle treatment; n = 7 WT, 6 KO mice for vehicle and 6 WT, 8 KO mice for rapamycin treatment; 5 mothers per treatment group. d mRNA expression levels of Osteocalcin (Ocn) in femurs of E18.5 mice measured by qRT-PCR; n = 9 WT, 5 KO mice for vehicle and 7 WT, 5 KO mice for rapamycin treatment
